富智康(02038.HK)向印度附属公司注资1亿美元
富智康(02038.HK)公布,於本月4日,公司於新加坡注册成立之间接全资附属公司Wonderful
Stars将会向其於印度注册成立之直接附属公司Rising Stars注资总金额近1亿美元作多种用途,包括用於业务扩展及作为额外营运资金。
Rising Stars於紧随该注资後之已发行股本总额将增至238.09亿印度卢比,其中99.97%由Wonderful Stars持有,余下0.03%由公司於新加坡注册成立之另一家间接全资附属公司Aptech Electronics Pte. Ltd.持有。
Rising Stars之主要业务为生产手机、通讯工具及电子产品连同相关软件专利及程式。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.